Responsible for the patent portfolio drafting and filing strategy for Rodin Therapeutics Inc, and handled IP negotiation and diligence matters relating to Rodin’s acquisition by Alkermes plc (Nasdaq: ALKS). Rodin focuses on developing small molecule therapeutics for synaptopathies, which are diseases of the central nervous system related to a dysfunction of synapses.
McCarter & English, LLP | Contents of this website may contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.